Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3Â weeks in solid tumours: An ECSG/EORTC study
Keywords: Phase I; Solid tumours; CHS 828; Chemotherapy; EORTC;